Ocumetics Technology Corp (OTC) AI Stock Analysis

• Market Cap: C$15.98M
• Dividend Yield: N/A
• Average Volume (3M): 35.16K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.20
• Revenue Growth: N/A
• EPS Growth: 18.30%
• Country: CA
• Employees: N/A
• Sector: Technology
• Sector Strength: 83
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 43,194,980
• 10 Day Avg. Volume: 41,499
• 30 Day Avg. Volume: 35,155
• PEG Ratio: -0.08
• Price to Book (P/B): 52.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 23 Underperform
• Price Target: ―

Ocumetics Technology Corp is facing significant financial challenges, marked by a lack of revenue generation, negative profitability, and a strained balance sheet with high liabilities. Technical analysis indicates a neutral trend with potential for slight upward movement, but valuation metrics remain unattractive. Recent corporate events show positive strategic developments, but they are not sufficient to outweigh the overall financial instability.

Ocumetics Technology Corp Business Overview & Revenue Model

Company Description

Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. The company is headquartered in Calgary, Canada.

How the Company Makes Money

Ocumetics Technology Corp generates revenue primarily through the development and sale of its proprietary eye care products. The company's main revenue stream comes from the commercialization of its advanced lens technologies, which are sold to healthcare providers, clinics, and directly to consumers. Ocumetics may also engage in strategic partnerships and licensing agreements with other companies in the healthcare and optical industries, which can provide additional income through royalties or shared revenue models. Furthermore, the company might receive funding and support through research grants or investment from healthcare-focused venture capital firms.

Ocumetics Technology Corp Financial Statement Overview

Summary

Ocumetics Technology Corp faces significant financial challenges, with no revenue generation and negative profitability metrics. The balance sheet is strained with negative equity and high liabilities. Cash flow issues persist, with negative operating and free cash flows. Immediate strategic plans are required to improve revenue generation, financial stability, and cash flow management.

Income Statement

The company has consistently reported zero revenue over the analyzed periods, resulting in negative net income and EBIT margins. The gross profit and other profitability metrics are negative due to the lack of revenue generation, highlighting significant challenges in achieving sales growth and profitability.

Balance Sheet

The company exhibits high leverage with a negative stockholder's equity position, indicating more liabilities than assets. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative. These factors suggest financial instability and a need for improved capital management.

Cash Flow

Operating and free cash flows are consistently negative, reflecting poor cash generation from operations. While some cash inflow exists from financing activities, it is insufficient to cover operating losses, raising concerns about liquidity and sustainability without external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Sep 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-134.30K	-117.62K	-102.21K	-96.18K	0.00
	EBIT
-2.43M	-3.61M	-2.22M	-598.19K	-172.49K
	EBITDA
-2.29M	-3.50M	-2.09M	-3.42M	-99.35K
	Net Income Common Stockholders
-3.02M	-3.64M	-2.22M	-598.19K	-172.49K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.57M	235.83K	602.09K	83.90K	224.35K
	Total Assets
2.32M	1.04M	1.37M	825.25K	225.32K
	Total Debt
3.95M	321.64K	292.34K	0.00	0.00
	Net Debt
3.76M	85.81K	-309.75K	-83.90K	-224.35K
	Total Liabilities
4.26M	945.33K	536.45K	1.10M	17.94K
	Stockholders Equity
-1.94M	91.10K	837.40K	-270.50K	207.38K
Cash Flow		Free Cash Flow
-2.51M	-2.19M	-1.69M	-213.63K	-817.00
	Operating Cash Flow
-2.43M	-2.05M	-1.62M	-89.13K	-817.00
	Investing Cash Flow
-1.46M	-142.17K	-66.82K	-214.92K	0.00
	Financing Cash Flow
3.85M	1.82M	444.35K	387.11K	0.00

Ocumetics Technology Corp Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OTC, the sentiment is Positive. The current price of 0.38 is below the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.34, and above the 200-day MA of 0.32, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 56.05 is Neutral, neither overbought nor oversold. The STOCH value of 15.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OTC.

Ocumetics Technology Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$11.91B	9.99	-7.22%	4.96%	7.31%	-8.91%
VXTR	39 Underperform	C$7.71M	―	-2108.66%	―	-47.00%	-22.30%
HEAT	33 Underperform	C$8.98M	―	-9999.00%	―	―	9.55%
OTC	23 Underperform	C$15.98M	―	171.44%	―	―	18.30%
BONE		C$9.25M	―	-8.76%	―	―	―
POND	31 Underperform	C$1.71M	―		―	-38.40%	33.22%
IOT		C$11.47M	29.49	22.65%	―	―	―

Ocumetics Technology Corp Corporate Events

Ocumetics Technology Corp. Announces Board Resignation Amid Vision Correction Innovations

Ocumetics Technology Corp. announced the resignation of Mr. Dayton Marks from its board of directors, with gratitude expressed for his contributions. This corporate change comes as the company continues to develop its groundbreaking intraocular lens technology, which aims to eliminate the need for corrective lenses by allowing natural eye muscle activity to provide clear vision at all distances.

Spark’s Take on TSE:OTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Underperform.

Ocumetics Technology Corp is facing significant financial challenges, marked by a lack of revenue generation, negative profitability, and a strained balance sheet with high liabilities. Technical analysis indicates a neutral trend with potential for slight upward movement, but valuation metrics remain unattractive. Recent corporate events show positive strategic developments, but they are not sufficient to outweigh the overall financial instability.

To see Spark’s full report on TSE:OTC stock, click here.

Ocumetics Advances Toward First-In-Human Clinical Trials for Innovative Lens

Ocumetics Technology Corp. has announced the completion of key milestones for its First-In-Human clinical study of the Ocumetics Lens, an accommodating intraocular lens designed to restore natural vision without corrective lenses. The company plans to begin the clinical trials in the summer of 2025, with initial results expected shortly thereafter. This development marks a significant step in Ocumetics’ efforts to revolutionize vision restoration for cataract patients and could have a transformative impact on the ophthalmic industry.

Spark’s Take on TSE:OTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Underperform.

The overall score reflects significant financial challenges, including lack of revenue generation, negative profitability metrics, and strained balance sheet with high liabilities. Technical indicators suggest a neutral trend with potential for slight upward movement. The valuation remains unattractive due to a negative P/E ratio and no dividends, highlighting the need for strategic improvements to enhance financial stability and investor appeal.

To see Spark’s full report on TSE:OTC stock, click here.

Ocumetics Technology Corp. Strengthens Board with New Appointment

Ocumetics Technology Corp. has appointed Michael L. Edwards to its Board of Directors, bringing extensive expertise in accounting, taxation, corporate governance, and fundraising. This strategic addition is expected to support Ocumetics’ growth phase, potentially strengthening its position in the ophthalmic technology industry and benefiting stakeholders through enhanced corporate governance and financial strategies.